These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 23586880)

  • 1. XIAP antisense therapy with AEG 35156 in acute myeloid leukemia.
    Katragadda L; Carter BZ; Borthakur G
    Expert Opin Investig Drugs; 2013 May; 22(5):663-70. PubMed ID: 23586880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38- cells in a phase 1/2 study of patients with relapsed/refractory AML.
    Carter BZ; Mak DH; Morris SJ; Borthakur G; Estey E; Byrd AL; Konopleva M; Kantarjian H; Andreeff M
    Apoptosis; 2011 Jan; 16(1):67-74. PubMed ID: 20938744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulling the plug on a cancer cell by eliminating XIAP with AEG35156.
    LaCasse EC
    Cancer Lett; 2013 May; 332(2):215-24. PubMed ID: 22776562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AEG-35156, an antisense oligonucleotide against X-linked inhibitor of apoptosis for the potential treatment of cancer.
    Tamm I
    Curr Opin Investig Drugs; 2008 Jun; 9(6):638-46. PubMed ID: 18516763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML.
    Carter BZ; Mak DH; Schober WD; Koller E; Pinilla C; Vassilev LT; Reed JC; Andreeff M
    Blood; 2010 Jan; 115(2):306-14. PubMed ID: 19897582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML).
    Erba HP; Sayar H; Juckett M; Lahn M; Andre V; Callies S; Schmidt S; Kadam S; Brandt JT; Van Bockstaele D; Andreeff M
    Invest New Drugs; 2013 Aug; 31(4):1023-34. PubMed ID: 23397500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP.
    Cummings J; Ward TH; LaCasse E; Lefebvre C; St-Jean M; Durkin J; Ranson M; Dive C
    Br J Cancer; 2005 Feb; 92(3):532-8. PubMed ID: 15685240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. XIAP downregulation promotes caspase-dependent inhibition of proteasome activity in AML cells.
    Carter BZ; Mak DH; Wang Z; Ma W; Mak PY; Andreeff M; Davis RE
    Leuk Res; 2013 Aug; 37(8):974-9. PubMed ID: 23669290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting XIAP for the treatment of malignancy.
    Schimmer AD; Dalili S; Batey RA; Riedl SJ
    Cell Death Differ; 2006 Feb; 13(2):179-88. PubMed ID: 16322751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia.
    Schimmer AD; Estey EH; Borthakur G; Carter BZ; Schiller GJ; Tallman MS; Altman JK; Karp JE; Kassis J; Hedley DW; Brandwein J; Xu W; Mak DH; LaCasse E; Jacob C; Morris SJ; Jolivet J; Andreeff M
    J Clin Oncol; 2009 Oct; 27(28):4741-6. PubMed ID: 19652057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II study.
    Schimmer AD; Herr W; Hänel M; Borthakur G; Frankel A; Horst HA; Martin S; Kassis J; Desjardins P; Seiter K; Fiedler W; Noppeney R; Giagounidis A; Jacob C; Jolivet J; Tallman MS; Koschmieder S
    Clin Lymphoma Myeloma Leuk; 2011 Oct; 11(5):433-8. PubMed ID: 21729686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis.
    LaCasse EC; Cherton-Horvat GG; Hewitt KE; Jerome LJ; Morris SJ; Kandimalla ER; Yu D; Wang H; Wang W; Zhang R; Agrawal S; Gillard JW; Durkin JP
    Clin Cancer Res; 2006 Sep; 12(17):5231-41. PubMed ID: 16951243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of X-linked inhibitor of apoptosis protein (XIAP) is an independent unfavorable prognostic factor in childhood de novo acute myeloid leukemia.
    Sung KW; Choi J; Hwang YK; Lee SJ; Kim HJ; Kim JY; Cho EJ; Yoo KH; Koo HH
    J Korean Med Sci; 2009 Aug; 24(4):605-13. PubMed ID: 19654940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of XIAP antisense to cancer and other proliferative disorders: development of AEG35156/ GEM640.
    Lacasse EC; Kandimalla ER; Winocour P; Sullivan T; Agrawal S; Gillard JW; Durkin J
    Ann N Y Acad Sci; 2005 Nov; 1058():215-34. PubMed ID: 16394139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions.
    Rosato RR; Almenara JA; Kolla SS; Maggio SC; Coe S; Giménez MS; Dent P; Grant S
    Mol Cancer Ther; 2007 Feb; 6(2):692-702. PubMed ID: 17308065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulation of XIAP by AEG35156 in paediatric tumour cells induces apoptosis and sensitises cells to cytotoxic agents.
    Holt SV; Brookes KE; Dive C; Makin GW
    Oncol Rep; 2011 Apr; 25(4):1177-81. PubMed ID: 21286665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. X-linked inhibitor of apoptosis protein represents a promising therapeutic target for relapsed/refractory ALL.
    Carlet M; Schmelz K; Vergalli J; Herold T; Senft D; Jurinovic V; Hoffmann T; Proba J; Weichert N; Junghanß C; Roth M; Eschenburg G; Barz M; Henze G; Eckert C; Eggert A; Zuber J; Hundsdoerfer P; Jeremias I
    EMBO Mol Med; 2023 Jan; 15(1):e14557. PubMed ID: 36416169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of Respiration and Mitochondrial Dynamics by SMAC-Mimetics for Combination Therapy in Chemoresistant Cancer.
    Hagenbuchner J; Oberacher H; Arnhard K; Kiechl-Kohlendorfer U; Ausserlechner MJ
    Theranostics; 2019; 9(17):4909-4922. PubMed ID: 31410190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo.
    Hu Y; Cherton-Horvat G; Dragowska V; Baird S; Korneluk RG; Durkin JP; Mayer LD; LaCasse EC
    Clin Cancer Res; 2003 Jul; 9(7):2826-36. PubMed ID: 12855663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. X-linked inhibitor of apoptosis inhibition sensitizes acute myeloid leukemia cell response to TRAIL and chemotherapy through potentiated induction of proapoptotic machinery.
    Zhou J; Lu X; Tan TZ; Chng WJ
    Mol Oncol; 2018 Jan; 12(1):33-47. PubMed ID: 29063676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.